Results 71 to 80 of about 25,234 (166)

SGLT2 Inhibitor-Associated Changes in Urinary Volatile Organic Compounds in Diabetic Kidney Disease: A Comprehensive Study. [PDF]

Nephrology (Carlton)
Hara R, Yamahara H, Hirakawa Y, Hashiba T, Keying H, Tabata H, Nangaku M.   +6 more
europepmc   +1 more source

Diabetic Ketoacidosis Associated With Painless Thyroiditis in a Patient Treated With an SGLT2 Inhibitor. [PDF]

Case Rep Endocrinol
Aotani R, Ohkuma T, Oshiro A, Okamura K, Ago T.   +4 more
europepmc   +1 more source

Efficacy and safety of SGLT2 inhibitor on insulin resistance and hyperglycemia in Werner syndrome-A case report. [PDF]

J Diabetes Investig
Yagi T, Aotani D, Hasegawa C, Shimizu Y, Koyama H, Maezawa Y, Yokote K, Tanaka T.   +7 more
europepmc   +1 more source

SGLT2 inhibitor therapy in diabetic cats: first clinical experiences with non-ideal candidates. [PDF]

J Feline Med Surg
Vanneste A, Van Heuckelom E, Vannieuwenhuyse D, De Voogt C, Daminet S.   +4 more
europepmc   +1 more source

Diabetic remission in a newly diagnosed diabetic cat treated with SGLT2 inhibitor. [PDF]

JFMS Open Rep
Lodarski F, Benchekroun G, Cervone M.
europepmc   +1 more source

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex. [PDF]

Diabetes Obes Metab
Yang C, Denig P, Chepulis L, Paul RG, Shin JI, Gansevoort RT, Vart P.   +6 more
europepmc   +1 more source

Case Report: Euglycemic ketoacidosis in a non-diabetic patient: a rare adverse effect of SGLT2 inhibitor therapy. [PDF]

Front Endocrinol (Lausanne)
Prasad S, Sharma S, Shetty R, Singh S, Parmar V, Shivaprasad C, Dhaduk V.   +6 more
europepmc   +1 more source

The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes. [PDF]

BMC Nephrol
Li C, Ng JKC, Chan GCK, Fung WWS, Chow KM, Szeto CC.   +5 more
europepmc   +1 more source

Non-Coding RNA in Type 2 Diabetes Cardio-Renal Complications and SGLT2 Inhibitor Response. [PDF]

Int J Mol Sci
Rykova E, Shmakova E, Damarov I, Merkulova T, Kzhyshkowska J.   +4 more
europepmc   +1 more source

Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes-A Real-World Study. [PDF]

Medicina (Kaunas)
Mateoc T, Suciu IM, Gaiță D, Minodora A, Popescu R, Vlad T, Flangea C, Muntean C, Vlad DC.   +8 more
europepmc   +1 more source